IP Library › Patent Application 18068682
Patent Application
App. No. 18/068,682

PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/068,682
Abstract

The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE. Figure: none

Claims (20)

1 . A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist.

2 . The method according to claim 1 , wherein said antagonist is a small molecule antagonist.

3 . The method according to claim 1 , wherein said antagonist has formula (I)

or pharmaceutically acceptable salts thereof, wherein n is 0 or 1; m is 1, 2 or 3; R 1 is H, C 1 -C 3 alkyl, halogenated C 1 -C 3 alkyl or cyclopropyl; R 2 is 4-chlorophenyl or 2,4,6-trichlorophenyl.

4 . The method according to claim 1 , wherein said PTGDR-1 antagonist is laropiprant.

5 . The method according to claim 1 , wherein said PTGDR-1 antagonist is used in combination with at least a PTGDR-2 antagonist.

6 . The method according to claim 5 , wherein said PTGDR-2 antagonist has formula formula (VIII)

wherein R1 is H, fluorine, methyl, methoxy, benzyloxy, or hydroxyl,

R2 is phenyl which is substituted by fluorine, chlorine, trifluoromethyl, methyl, ethyl, propyl, isopropyl, or methoxy, and

Y is 0 or 1,

or pharmaceutically acceptable salts thereof.

7 . The method according to claim 6 , wherein said PTGDR-2 antagonist is CAY10471 (TM30089).

8 . The method according to claim 5 , wherein said PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in a single pharmaceutical composition.

9 . The method according to claim 5 , wherein said PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in separate pharmaceutical compositions for simultaneous use, separate use, or use spread over time.

10 . The method according to claim 1 , wherein said PTGDR-1 antagonist is a dual PTGDR-1/PTGDR-2 antagonist.

11 . A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a pharmaceutical composition comprising a PTGDR-1 antagonist and a PTGDR-2 antagonist, or a dual PTGDR-1/PTGDR-2 antagonist.

12 . A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist and a PTGDR-2 antagonist as a combined preparation for simultaneous use, separate use, or use spread over time.

13 . A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-2 antagonist.

14 . The method according to claim 1 , wherein the PTGDR-1 antagonist prevents basophil homing to secondary lymphoid organs.

15 . The method according to claim 1 , wherein the PTGDR-1 antagonist prevents, limits the extent or reduces the increase in autoantibody titers and/or the occurrence of SLE flares and/or organ damages.